Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTK | P33981 | 4/20 | 0.57 |
| ▸ | AURKA | O14965 | 4/20 | 0.50 |
| ▸ | FYN | P06241 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | FLT3 | P36888 | 2/20 | 0.46 |
| ▸ | SRC | P12931 | 1/20 | 0.46 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.46 |
| ▸ | MAPKAPK5 | Q8IW41 | 4/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25447053 | 0.86 | TTK (0.54) | TTKAURKAFYNSRCAURKB | |
| SCHEMBL3466981 | 0.86 | SRC (0.56) | TTKAURKAFYNLMNAMAPK1 | |
| SCHEMBL25447060 | 0.84 | TTK (0.54) | TTKAURKAFYNFLT3SRC | |
| SCHEMBL12409302 | 0.82 | TTK (0.66) | TTKAURKAFYNSRCAURKB | |
| SCHEMBL25447058 | 0.82 | TTK (0.57) | TTKAURKAFYNSRCAURKB | |
| SCHEMBL25014253 | 0.81 | TTK (0.56) | TTKAURKASRCMAPKAPK5 | |
| SCHEMBL5403440 | 0.81 | FLT3 (0.59) | TTKFLT3AURKBKDR | |
| SCHEMBL8247273 | 0.79 | AURKA (0.69) | TTKAURKAFYNSRCAURKB | |
| SCHEMBL14767444 | 0.79 | TTK (0.54) | TTKAURKAFYNKDM4ESRC | |
| SCHEMBL3471147 | 0.79 | MAPK1 (0.56) | TTKAURKAFYNLMNAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230141403-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230141403-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | XDH, MYD88, IKZF3 | TTK 4157/4885AURKA 2897/4885FYN 3892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.